Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 3/20 | 0.71 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | BTK | Q06187 | 3/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017578 | 0.84 | TGM2 (1.00) | TGM2EGFRALDH1A1NPC1RAB9A | |
| SCHEMBL14341775 | 0.83 | TGM2 (0.86) | TGM2EGFRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14791233 | 0.80 | EGFR (0.73) | EGFRNPC1RAB9AGAAHPGD | |
| SCHEMBL14165785 | 0.80 | BTK (0.84) | TGM2EGFRALDH1A1BTK | |
| SCHEMBL14165468 | 0.80 | BTK (0.84) | TGM2EGFRALDH1A1BTK | |
| SCHEMBL160408 | 0.79 | TP53 (0.68) | TGM2ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL12519481 | 0.78 | EGFR (1.00) | EGFRBTK | |
| SCHEMBL16198404 | 0.78 | RNF4 (0.71) | ALDH1A1NPC1RAB9AHTTTDP1 | |
| SCHEMBL17531746 | 0.78 | MTNR1A (0.61) | EGFRALDH1A1NPC1RAB9AHTT | |
| SCHEMBL16198117 | 0.78 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9AHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | TGM2 2225/4885EGFR 2875/4885ALDH1A1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.